Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: Evaluation by surface plasmon resonance and serotonin release assay

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 3, 2012, Pages 430-436

  Leroux, D ^a,b   Canepa S ^c   Viskov, C ^d   Mourier, P ^d   Herman, F ^d   Rollin, J ^a,b   Gruel, Y ^a,b   Pouplard, C ^a,b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c UMR85 PHYSIOLOGIE DE LA REPRODUCTION ET DES COMPORTEMENTS   (France)

^d SANOFI   (France)

Author keywords

Enoxaparin; Heparin induced thrombocytopenia; Oligosaccharides; Platelet factor 4; Serotonin release assay; Surface plasmon resonance

Indexed keywords

ANTITHROMBIN; CARBOHYDRATE; DEXTRAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; OLIGOSACCHARIDE; SULFATE; THROMBOCYTE FACTOR 4;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PRIORITY JOURNAL; RISK; SEROTONIN RELEASE; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; THROMBOCYTE ACTIVATION;

ANTIBODIES; ANTICOAGULANTS; BINDING SITES, ANTIBODY; BLOOD PLATELETS; CASE-CONTROL STUDIES; ENOXAPARIN; HUMANS; MOLECULAR STRUCTURE; PLATELET ACTIVATION; PLATELET FACTOR 4; RISK ASSESSMENT; RISK FACTORS; SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; THROMBOCYTOPENIA;

EID: 84857508589     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04618.x     Document Type: Article

References (21)

1. Lindahl U, Li JP. Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol 2009; 276: 10-59.
2. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
3. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002; 41: 391-412.
4. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. Annu Rev Med 2010; 61: 77-90.
5. Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu WY, Arepally G, Shoenfeld Y, KieberEmmons T, Cines DB, Poncz M. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998; 92: 3250-9.
6. Li ZQ, Liu W, Park KS, Sachais BS, Arepally GM, Cines DB, Poncz M. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002; 99: 1230-6.
7. Thompson CA. FDA approves first generic enoxaparin product. Am J Health Syst Pharm 2010; 67: 1486, 1488.
8. Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost 2008; 34: 74-85.
9. Harenberg J. Overview on guidelines and recommendations for generic low-molecular-weight heparins. Thromb Res 2011; 127 (Suppl. 3): S100-4.
10. Pouplard C, Amiral J, Borg JY, Vissac AM, Delahousse B, Gruel Y. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol 1997; 99: 273-80.
11. Mourier PA, Viskov C. Chromatographic analysis and sequencing approach of heparin oligosaccharides using cetyltrimethylammonium dynamically coated stationary phases. Anal Biochem 2004; 332: 299-313.
12. Guerrini M, Elli S, Gaudesi D, Torri G, Casu B, Mourier P, Herman F, Boudier C, Lorenz M, Viskov C. Effects on molecular conformation and anticoagulant activities of 1, 6-anhydrosugars at the reducing terminal of antithrombin-binding octasaccharides isolated from low-molecular-weight heparin enoxaparin. J Med Chem 2010; 53: 8030-40.
13. Piliarik M, Vaisocherova H, Homola J. Surface plasmon resonance biosensing. Methods Mol Biol 2009; 503: 65-88.
14. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106: 2710-5.
15. Amiral J, Bridey F, Dreyfus M, Vissac A, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6.
16. Denton J, Lane DA, Thunberg L, Slater AM, Lindhal U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983; 209: 455-60.
17. Guerrini M, Guglieri S, Casu B, Torri G, Mourier P, Boudier C, Viskov C. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue. J Biol Chem 2008; 283: 26662-75.
18. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 886-92.
19. Walenga JM, Jeske WP, Prechel MM, Bacher P, Bakhos M. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Semin Thromb Hemost 2004; 30 (Suppl. 1): 69-80.
20. Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 3rd edn. New York, NY, Basel: Marcel Dekker, Inc, 2004: 197-221.
21. Warkentin TE. Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol 2010; 3: 567-81.